Search the Newsreel

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rallybio Corp (RLYB) has an earnings forecast score of 6.00, placing it 330 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.00 for RLYB, with recent EPS at -$1.03 against an expectation of -$1.46. …

Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS

Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary

Rallybio Corp reported Q2 2026 results with $0 revenue and a net income of $43.67 million, or $7.53 diluted EPS, a significant increase from a net loss in the prior year. This financial improvement was driven by strategic transactions, including a $50 million termination …

Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in Rallybio Corp (RLYB), totaling 794,720 shares of common stock as of June 30, 2026. This stake includes a 5.0% holding by the Fidelity Growth Company Commingled Pool, amounting to 265,132 …

Rallybio (NASDAQ: RLYB) wins $50M fee, plans merger with Avenzo

Rallybio Corporation reported a significant swing to profitability in Q2 2026, driven by a $50 million termination fee from its canceled merger with Candid Therapeutics, resulting in a net income of $43.7 million. The company now plans to merge with Avenzo Therapeutics, a clinical-stage …

Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership

Laurion Capital Management LP and its co-managing members, Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, have filed an amended Schedule 13G for Rallybio (RLYB), reporting 0% beneficial ownership of the company's common stock. This filing indicates that Laurion Capital and its associated individuals no …

Rallybio Corporation Revenue Breakdown – NASDAQ:RLYB

Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rallybio Corp (RLYB), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -11.68 and indicates that relevant data for P/B, P/S, and P/CF ratios have …

Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs Persist - Geographic Revenue Trends

Rallybio (RLYB) to Release Quarterly Earnings on Thursday

Rallybio Corp (RLYB) Balance Sheet

This article provides a detailed balance sheet for Rallybio Corp (RLYB), offering quarterly and annual financial data spanning several years. It includes key financial metrics such as cash and investments, total assets, liabilities, and shareholders' equity, along with year-over-year changes. The report also features …

RLYB|Rallybio Corp|Price:16.065|Chg%:-0.245

This article provides a detailed introduction to Rallybio Corp (RLYB), a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. It outlines the company's business scope, key pipeline assets like RLYB116, RLYB332, and RLYB114, and lists its financial data, market performance, …

Rallybio Market Sentiment

This article provides an overview of market sentiment for Rallybio (RLYB), including an "Outperform" analyst consensus from 7 analysts with an average price target of $9, which is 44.3% below the current trading price. The company's short interest is 8.3% and declining, which is …

Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest

Rallybio Corporation (NASDAQ:RLYB) experienced a significant 58.4% decrease in short interest by July 15th, bringing the total to 170,156 shares. Despite insider buying, institutional ownership is high at 90.34%, and the company remains unprofitable with a consensus "Sell" rating. The stock opened at $16.31, …

RLYB Financials

This article provides a detailed financial overview of Rallybio Corp (RLYB), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and various margins over several quarters and fiscal years. The report also …

Rallybio Corp (RLYB) Institutional Confidence

Rallybio Corp (RLYB) has an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.82%, a slight decrease of 1.97% quarter-over-quarter. Andreas Halvorsen is the largest institutional shareholder, holding …

Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rallybio Corp (RLYB), detailing its current price momentum score, support and resistance levels, and a comprehensive breakdown of technical indicators and moving averages. The analysis suggests a "Neutral" signal for the stock based on these indicators, noting …

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

Rallybio Corporation Q1 2026 Earnings: Wider Loss Reflects R&D Investment, Stock Gains - Forward Guidance Trends

Rallybio reverse split swaps 8 shares for 1, cash for fractions

What is the current Price Target and Forecast for Rallybio (RLYB)